Applied Therapeutics, Inc. (APLT) - Dilution Analysis

10-Q filing | 145.6M shares outstanding

8-K filing: Applied Therapeutics, Inc. may offer and sell shares of its common stock with an aggregate offering price of up to $75,000,000 through Cantor Fitzgerald & Co. Also, Applied Therapeutics, Inc. terminated the Leerink Partners Sales Agreement, after selling 20,615,976 shares of Common Stock for net proceeds of approximately $49.3 million. ($49.3M proceeds)

10-Q filing | 145.1M shares outstanding

10-Q filing | 144.8M shares outstanding

10-K filing | 139.5M shares outstanding

10-Q filing | 116.4M shares outstanding

10-Q filing | 114.8M shares outstanding

10-Q filing | 125.3M shares outstanding

S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to 14,285,714 shares of common stock for resale by selling stockholders, including 2,000,000 shares issuable upon exercise of pre-funded warrants.

10-K filing | 105.9M shares outstanding

10-Q filing | 77.2M shares outstanding

8-K filing: Applied Therapeutics, Inc. entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners, exchanging 5,658,034 shares of common stock for pre-funded warrants to purchase 5,658,034 shares of common stock, with an exercise price of $0.001 per share.

10-Q filing | 63.1M shares outstanding

S-3 filing: The filing is an S-3 registration statement for Applied Therapeutics, Inc., covering the potential issuance of common stock upon warrant exercises, resale of common stock by selling stockholders, and other securities up to an aggregate offering price of $300,000,000.

10-Q filing | 56.4M shares outstanding

8-K filing: Applied Therapeutics, Inc. completed a private placement on April 26, 2023, selling 9,735,731 shares of common stock and 22,000,000 pre-funded warrants at $0.946 per share/warrant, resulting in gross proceeds of approximately $30 million. ($60.0M proceeds)

10-K filing | 48.1M shares outstanding

10-Q filing | 48.0M shares outstanding

10-Q filing | 46.3M shares outstanding

8-K filing: Applied Therapeutics, Inc. closed an underwritten public offering on June 27, 2022, involving the issuance and sale of 20,000,000 shares of common stock, 10,000,000 pre-funded warrants, and accompanying warrants to purchase up to 30,000,000 shares of common stock, with Alexandria Venture Investments, LLC purchasing 3,500,000 shares and 1,500,000 Pre-Funded Warrants. ($30.0M proceeds)

10-Q filing | 26.2M shares outstanding

10-K filing | 25.6M shares outstanding

10-Q filing | 26.2M shares outstanding

10-Q filing | 26.1M shares outstanding

10-Q filing | 26.1M shares outstanding

10-K filing | 26.0M shares outstanding

8-K filing: Applied Therapeutics, Inc. completed a public offering of 3,000,000 shares of common stock at a price of $23.00 per share on February 17, 2021.

10-Q filing | 22.5M shares outstanding

10-Q filing | 22.4M shares outstanding

S-3/A filing: Applied Therapeutics, Inc. is offering up to $100,000,000 of common stock through an equity distribution agreement with Goldman Sachs & Co. LLC as a sales agent in "at-the-market" offerings.

S-3 filing: Applied Therapeutics, Inc. files an S-3 form to offer and sell up to $100,000,000 of its common stock through an equity distribution agreement with Goldman Sachs & Co. LLC as the sales agent, in at-the-market offerings.

POS AM filing: This POS AM filing describes an offering of 1,380,344 shares of common stock. The selling stockholders will receive all of the net proceeds from the sale of the shares, and the company will not receive any proceeds from this offering.

10-Q filing | 22.0M shares outstanding

POS AM filing: This POS AM filing from 2020-03-16 details a common stock offering of 1,380,344 shares, with 21,969,277 shares outstanding as of February 29, 2020.

10-K filing | 22.0M shares outstanding

S-1/A filing: This S-1/A filing includes information about the company's common stock offering, including the number of shares to be offered, outstanding shares, and the use of proceeds.

S-1 filing: This S-1 filing includes information on outstanding shares of common stock, voting rights, dividends, liquidation preferences, and rights of common stockholders. It also details a proposed offering of 1,750,000 shares of common stock at an assumed price of $48.86 per share, with an option for underwriters to purchase an additional 262,500 shares. The net proceeds are intended for advancing clinical trials, developing pipeline candidates, and general corporate purposes.